No Detail Found!

Prognostic Value of P53 Expression Intensity in Urothelial Cancers.

Author(s)
Samina Qamar Department of Pathology, King Edward Medical University, Lahore, Pakistan
Qazi Adil Inam Department of Urology, Nawaz Sharif Medical College, Gujrat, Pakistan
Sobia Ashraf Department of Pathology, King Edward Medical University, Lahore, Pakistan
M. Safdar Khan Department of Urology, King Edward Medical University, Lahore, Pakistan
M. Abbas Khokhar Department of Oncology, King Edward Medical University, Lahore, Pakistan
Nukhbatullah Awan Department of ENT, King Edward Medical University, Lahore, Pakistan
Abstract
Objective: To determine association of immunohistochemical expression intensity of p53 with grade and stage of urothelial cancers. Study Design: Descriptive cross-sectional analytical study. Place and Duration of Study: Pathology Department, King Edward Medical University, Lahore, from January to December 2016. Methodology: Data of transurethral resection/radical cystesctomy urinary bladder biopsies was collected. Clinical, radiological and cystoscopic findings of patients were noted from patients' charts in the Urology Ward. Biopsies were graded histologically according to WHO 2004 grading system. TNM system was used for pathological staging. On selected slides, immunoshistochemistry for p53 was applied. Nuclear immunoreactivity was considered positive if present in >10% of tumor cells and negative if <10% of tumor cells. Intensity was considered weak (less than 15% cells) and strong (more than 15% cells). Data was analyzed by SPSS version 21. Linear-by-linear association was calculated between p53 expression and stage of urothelial tumors, Chi-Square test was used to see association between grade and intensity of p53. Qualitative variables, like grade and stage of carcinoma along with p53 expression, were calculated in terms of frequencies and percentages. P = 0.05 was taken as significant. Results: Out of the 70 patients, 61 (87%) were males and 9 (13%) females. Out of 25 low grade lesions, 4 (16%) cases were p53 positive; and out of 45 high grade lesions, 41 (91%) cases were p53 positive. There was 33% (2/6 cases) positivity in Tis, 55% (16/29 cases) in T1, 72% in T2 (21/29), and 100% in T3a (5/5 cases) and T3b (1/1 case). Strong intensity of p53 staining was noted to be 5.4% (n=25) of low grade and 94.6% (n=45) of high grade tumors. Conclusion: p53 expression was greater and more frequently strong in higher grade and stage of urothelial carcinoma. It can be used as a prognostic marker in predicting higher grade and stage of bladder cancer.
Publication Details
Page(s) 232-236
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 27, Issue: 4, Year: 2017

Request the full text from PASTIC

References
KumarV,AbbasAK,FaustoN,AsterJC, 2014.,Pathologic basis of disease. 9th ed -
RosaiJ,AckermanLV, 2011.,Surgical pathology. 10th ed. Vol I. Missouri -
AtiqueM,AbbasiMS,JamalS,KhadimMT,AkhtarF,JamalN., 2014.CD 10 expression intensity in various grades and stages of urothelial carcinoma of urinary bladder,J Coll Physiciains Surg Pak 24 351 -5
BabjukM,OosterlinckW,SylvesterR,KaasinenE,Paulo-RedortaJ, 2011.European association of urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update,Eur Urol 59 997 -1008
LeeJY,ChoKS,DiazRR,ChoiYD,ChoiHY, 2015.P53 expression as a prognostic factor in upper urinary tract urothelial carcinoma: A systematic review and meta-analysis,Urol Int 94 50 -7
2013.urinary bladder carcinoma,Indian J Pathol Microbiol 56 10 -5
SobinLH,WittekindC, 2002.,TNM classification of malignant tumors -
YildizIZ,RecavarrenR,ArmahHB,BastackyS,DhirR,ParwaniAV, 2009.Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in diagnosis of non-neoplastic and neoplastic bladder biopsies,Diagn Pathol 4 35 -
SunW,ZhangPL,HerreraGA, 2002.p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder,Appl Immunohistochem Mol Morphol 10 327 -31
PoletajewS,BiernackiR,BuraczynskiP,ChojnackiJ,CzarnackiJ,GajewskaD, 2016.Stage of bladder cancer in central Europe-Polish perspective,Neoplasma 63 642 -7
TunaB,YorukogluK,DuzcanE,SenS,NeseN,SariskB, 2011.Histological grading of papillary urothelial neoplasm: Impact of combined grading (two numbered grading system) on reproducibility,Virchows Arch 458 659 -64
SharmaP,KiniH,PaiRR,SahuKK,KiniJ, 2015.Study of the reproducibility of 2004 World Health Organization classification of urothelial neoplasms,Indian J Pathol Microbiol 58 59 -61
ComperatE,LarreS,RoupretM,NeuzilletY,PignotG,QuintensH, 2015.Clinicopathological charecteristics of urothelial bladder cancer in patients less than 40 years old,Virchows Arch 466 589 -94
NaeemA,NaseemN,AnwarS,ButtS,NagiAH, 2015.Clinicopathological pattern classification and staging of urinary bladder carcinomas - A five-year experience at a tertiary care hospital in central Punjab,J Ayub Med Coll Abbottabad 27 131 -4
Ying-YingWang,Jie-WeiChen,TaoQin, 2015.Bladder papillary urothelial neoplasm of low malignant potential in Chinese: A clinical and pathological analysis,Int J Clin Exp Pathol 8 5549 -55
LaishramRS,KipgenP,LaishramS,KhuraijamS,SharmaDC, 2012.Urothelial tumors of urinary bladder in Manipur: A histopathological perspective,Asian Pac J Cacer Prev 13 2477 -9
KawaguchiM,HaraN,BilimV,KoikeH,SuzukiM,KimTS, 2016.A diagnostic marker for superficial urothelial bladder carcinoma: Lack of nuclear ATBF1 (ZFHX3) by immunohistochemistry suggests malignant progression,BMC Cancer 16 805 -
BoegemannM,KrabbeLM, 2016.Prognostic implications of immunohistochemical biomarkers in non-muscle invasive bladder cancer and muscle-invasive bladder cancer,Mini Rev Med Chem -
StadlerWM,LernerSP,GroshenS,SteinJP,ShiSR,RaghavanD, 2011.Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status,J Clin Oncol 29 3443 -9
KoyuncuerA, .Immunohistochemical expression of p63, p53 in, -
BraitM,MunariE,LeBronC,NoordhuisMG,BegumS,MichailidiC, 2013.Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma,Cell Cycle 12 1058 -70
RoychowdhuryA,DeyRK,BandyapadhyayA,BhattacharyaP,MitraRB,DuttaR, 2012.Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder,J Indian Med Assoc 110 393 -6
HeF,MelamedJ,TangMS,HuangC,WuXR, 2015.Oncogenic HRAS activates epithelial to mesenchymal transition and confers stemness to p53-deficient urothelial cells to drive muscle invasion of basal subtypes carcinomas,Cancer Res 75 2017 -28
ZhouH,HeF,MendolsohnCL,TangMS,HuangC,WuXR, 2016.FGFR3b loop extracellular loop mutation lacks tumorigenicity in vivo but collaborates with p53/pRB deficiency to induce high grade papillary urothelial carcinoma,Sci Rep 6 25596 -
0

Citations

0

Downloads

77

Views